ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
Researchers developed a CAR-T manufacturing strategy using the cytokine fusion scaffold HCW9206 to generate longer-lasting ...
Add Yahoo as a preferred source to see more of our stories on Google. A Nature Immunology study suggests PARP inhibitors can reprogram CD8 T cells into longer-lasting “superior memory” cancer fighters ...
Immunotherapy has revolutionized the way physicians treat patients. Previously, chemotherapy was the standard-of-care with the goal to eliminate tumor cells by dysregulating their ability to ...
A breakthrough study published today in the Journal of Neuroscience sheds new light on how brain cells relay critical information from their extremities to their nucleus, leading to the activation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results